Infections occurring in immunocompromised patients after intensive chemotherapy are often difficult to eradicate and are capable of even being fatal. New emergent and dangerous drug-resistant micro-organisms are likely to appear in these specific scenarios. Clinical features mainly include progressive pneumonia, bacteriemia/fungemia, or extrapulmonary dissemination among infections. The treatment of these microorganisms is still an open challenge since there is a lack of clear treatment guidelines. Indeed, infections from these microorganisms can lead to a rapidly fatal clinical course in immunocompromised patients, especially those who have acute leukemia. We describe the case of a young patient with acute myeloid leukemia who contracted an infection from Saprochaete capitata during post-chemotherapy aplasia.

Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases

Duminuco, Andrea
;
Vetro, Calogero;Maugeri, Cinzia;Mauro, Elisa;Palumbo, Giuseppe A;Parisi, Marina S;Esposito, Benedetta;Giuliano, Giuseppe;Romano, Alessandra;Di Raimondo, Francesco
2022-01-01

Abstract

Infections occurring in immunocompromised patients after intensive chemotherapy are often difficult to eradicate and are capable of even being fatal. New emergent and dangerous drug-resistant micro-organisms are likely to appear in these specific scenarios. Clinical features mainly include progressive pneumonia, bacteriemia/fungemia, or extrapulmonary dissemination among infections. The treatment of these microorganisms is still an open challenge since there is a lack of clear treatment guidelines. Indeed, infections from these microorganisms can lead to a rapidly fatal clinical course in immunocompromised patients, especially those who have acute leukemia. We describe the case of a young patient with acute myeloid leukemia who contracted an infection from Saprochaete capitata during post-chemotherapy aplasia.
2022
Saprochaete capitata; emergent and multiresistant micro-organisms; hematological malignancies; immunocompromised patients; voriconazole
File in questo prodotto:
File Dimensione Formato  
hematolrep-14-00011.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 781.19 kB
Formato Adobe PDF
781.19 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/533020
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 4
social impact